ATAI Life Sciences BV Cash Flow-to-Debt Ratio
ATAI Life Sciences BV cash flow-to-debt ratio. ATAI Life Sciences BV (ATAI) has a Cash Flow-to-Debt Ratio of -0.32x as of March 2026, meaning its operating cash flow of $-21.09 Million could theoretically repay 0% of its total liabilities ($66.10 Million) in one year. Check ATAI Life Sciences BV cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ATAI Life Sciences BV (2019–2025)
Cash flow-to-debt ratio of ATAI Life Sciences BV from 2019 to 2025. Historical debt coverage capacity for ATAI Life Sciences BV across 7 annual periods. Check ATAI Life Sciences BV cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ATAI Life Sciences BV Cash Flow-to-Debt Ratio by Year (2019–2025)
ATAI Life Sciences BV cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for ATAI Life Sciences BV. For the full cash flow conversion analysis, see ATAI cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.16x | $-102.67 Million | $88.54 Million | ▲ +39.7% |
| 2024 | -1.92x | $-82.44 Million | $42.83 Million | ▼ -12.5% |
| 2023 | -1.71x | $-84.12 Million | $49.16 Million | ▲ +35.0% |
| 2022 | -2.63x | $-104.47 Million | $39.67 Million | ▼ -17.4% |
| 2021 | -2.24x | $-63.25 Million | $28.21 Million | ▼ -74.7% |
| 2020 | -1.28x | $-20.77 Million | $16.18 Million | ▲ +61.8% |
| 2019 | -3.36x | $-7.85 Million | $2.34 Million | — |